Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Incyte

Stocks With Rising Relative Price Strength: Incyte

Incyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.

Investors Business Daily

Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review

The stock market tested key levels but ultimately rallied, with many leaders flashing buy signals. Bitcoin raced toward $100,000.

Investors Business Daily

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Flashing Renewed Technical Strength: Incyte

Incyte sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

Incyte stock broke out Tuesday after sales of the company's two key products beat analysts' third-quarter projections.

Investors Business Daily

Is Incyte Stock Underperforming the Nasdaq?

Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers

Dow Jones tech giant Intel led the S&P 500 Monday, and kept running late. Apple chipmakers Qorvo and Skyworks sold off on iPhone 16 concerns.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Incyte Stock: Is Wall Street Bullish or Bearish?

While Incyte has underperformed the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.

Barchart

3 Value Stocks With Strong Fundamentals to Buy Now

Value investing is highly favored as it focuses on purchasing undervalued stocks with solid fundamentals, providing the potential for high returns with lower risk and a disciplined, long-term approach. Therefore, it could be wise to invest in fundamentally sound, value stocks Expedia Group (EXPE), Incyte (INCY), and Albertsons Companies (ACI)…

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Investors Business Daily

2 Best Growth Stocks to Buy with $1,000 Right Now

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

Barchart

3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable industry trends, investing in quality biotech stocks Organogenesis Holdings (ORGO), Genmab A/S (GMAB), and Incyte (INCY) could be…

StockNews.com

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review

The major indexes retreated for most of the week on banking fears, but rebounded Friday on a strong jobs report and bank stocks roaring back.

Investors Business Daily

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales

Incyte stock plummeted Tuesday as seasonality hacked at first-quarter revenue and profit with notable sales misses from Jakafi and Opzelura.

Investors Business Daily

S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday

Micron Technology and Charles Schwab were among the top S&P 500 stock performers on Monday. Expedia was a notable loser.

Investors Business Daily

Incyte Stock Dives On A Surprise Rejection For Its Biggest Moneymaker

Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Top-Notch Medical Stocks Incyte, Haemonetics Beat — And Shares Crumbled

Incyte stock fell Tuesday after topping quarterly expectations, while fellow medical outlet Haemonetics tumbled on its beat.

Investors Business Daily

Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

Incyte shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Investors Business Daily

9 Companies' Profit Set To Triple While S&P 500 In Free Fall

You might think fourth quarter earnings reports are ugly if you're just looking at the S&P 500. More than a few stocks buck the trend.

The Street

Is Incyte Building a Vitiligo Empire?

A recent acquisition could pair nicely with the commercial infrastructure being built for the recently-approved Opzelura.

Benzinga

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

1,424 stories

NIO

956 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.